Drug Study (Mircera)

Name of Student: Rene John Francisco Name of Client: Charlie Paclauna Name of the Drug Generic Name: Epoetin betamethoxy polyethylene glycol Trade name: Mircera Classification: Hematopoietic Growth Factors Dosage, Timing, Route 0.6 mcg/kg IV/SC q2 week Age: 71 years old Indication Year, Section, and Group: BN4-A; Group 2 Gender: Male Contraindi cations Contraindic ated in patients with uncontrolled hypertensio n Contradicte d in patients with a history of hypersensiti vity or allergy to the drug Adverse Reactions Nursing Responsibilities Date: December 13, 2012

Mechanism of Action

Mircera (methoxy Treatment of polyethylene glycolchronic kidney epoetin beta) is an disease anemia erythropoiesisstimulating agent (ESA). A primary growth factor for erythroid development, erythropoietin is produced in the kidney and released into the bloodstream in response to hypoxia. In responding to hypoxia, erythropoietin interacts with erythroid progenitor cells to increase red cell production. Production of endogenous erythropoietin is impaired in patients with chronic renal

VASCULARHypertension, Procedural Hypotension GASTROINTEST INAL- Diarrhea, Vomiting, Constipation INFECTIONS AND INFESTATIONSNasopharyngitis, Upper Respiratory Tract Infection, Urinary Tract Infection NERVOUS SYSTEM Headache MUSCULOSKEL ETAL AND CONNECTIVE

Do not use this medication if you are allergic to epoetin betamethoxy polyethylene glycol, if you have untreated or uncontrolled high blood pressure. Before using Mircera, tell your doctor if you have:

heart disease, congestive heart failure, or high blood pressure (hypertension); a history of stroke, heart attack, or blood clots; a blood cell or clotting disorder, such as sickle cell anemia or hemophilia; cancer; or epilepsy or another seizure disorder.

Use this medication exactly as it was prescribed for you. Do not use the medication in larger amounts, or use it for longer than recommended by your doctor. Follow the instructions on your prescription label. Mircera is usually given once every 2 weeks or once a month. Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of needles, IV tubing, and other items used in giving the medicine.

failure (CRF) and erythropoietin deficiency is the primary cause of their anemia.

TISSUEMuscle Spasms, Back Pain, Pain in Extremity METABOLISM AND NUTRITIONFluid Overload

Use a different place on your skin each time you give yourself an injection. Do not inject into the same place two times in a row. Do not shake the medication vial (bottle). Vigorous shaking can ruin the medicine. Do not draw your dose into a syringe until you are ready to give yourself an injection. Do not use the medication if it has changed colors or has any particles in it. Keep each vial or prefilled syringe in its original container until you are ready to use it. Each vial (bottle) or prefilled syringe of this medicine is for one use only. Throw away any medicine that is leftover after you use a vial or syringe. To be sure this medication is helping your body produce red blood cells, your blood will need to be tested on a regular basis. You may also need to check your blood pressure during treatment. Do not miss any scheduled appointments. It may take up to 6 weeks of using this medicine before your symptoms improve. For best results, keep using the medication as directed. Talk with your doctor if your symptoms do not improve after 6 weeks of treatment. Mircera is only part of a complete program of treatment that may also include diet, dialysis, and other medications. Follow your doctor's instructions very closely.

References:

Nursing 2007 Drug Handbook 27th Edition, Lippincot Williams & Wilkins Turkoski,B. Drug Information Hand book for Nurses. Multum, C. (2007, December 19). Drugs Online. Retrieved from Drugs Incorporated Web site: http://www.drugs.com/mircera.html